NNVC Advances Pipeline in Expanding Global Biotech Market ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.
 NV-387 by NanoViricides: A Revolutionary Therapy That Could Prevent Cancer Recurrence While Battling Deadly Viruses—Phase II Trials Underway! NanoViricides, Inc. (NYSE American: NNVC) is at the forefront of a potential medical revolution with its lead drug NV-387, now advancing into Phase II clinical trials. NV-387 is not just a powerful broad-spectrum antiviral—it may also prevent the recurrence of metastatic cancer in patients in remission! Research shows that viral infections, including COVID-19, Influenza, RSV, and measles, can awaken dormant cancer cells, driving metastasis. NV-387 works on two fronts: it attacks the virus while reducing harmful inflammation, particularly IL-6 cytokines, which studies link to cancer cell reactivation. In preclinical studies, NV-387 protected lungs from lethal viral infections while dramatically lowering inflammatory markers, outperforming existing antivirals like Tamiflu and Xofluza. This means NV-387 has unique first-in-class potential, combining lifesaving antiviral efficacy with groundbreaking cancer-prevention effects. The implications for patients and the market are massive. With viral infections surging globally and no therapy currently addressing both viral threats and the risk of metastatic cancer recurrence, NNVC’sNV-387 is positioned to meet a critical unmet medical need. NanoViricides’ exclusive nanoviricide™ platform technology ensures viruses cannot escape, even as new variants emerge, giving the drug a rare competitive edge. This is a company pioneering dual-benefit therapies that could transform antiviral treatment and cancer care simultaneously. With Phase II trials on the horizon, the clinical, commercial, and societal potential of NV-387 is extraordinary. Discover how NV-387’s dual mechanism and unmatched preclinical data make NanoViricides a company poised for transformative impact—financially and medically. |
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $5,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) by Small Caps Daily and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 09/15/2025. Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 More of today's hot market news at BehindtheMarkets.com >> Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
|
|
